Chlorinated lipids in sepsis
败血症中的氯化脂质
基本信息
- 批准号:9132272
- 负责人:
- 金额:$ 45.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdherenceAdmission activityAdultAldehydesAtherosclerosisBiochemicalBiochemistryBiological AssayBiological MarkersBiologyBloodBlood CellsBlood CirculationBlood PlateletsBlood VesselsCell Adhesion MoleculesCell CommunicationCell physiologyCellsChildClinicalClinical MicrobiologyCollaborationsComplexDataDilatation - actionDisciplineDiseaseEndothelial CellsEnvironmentFunctional disorderHealthHospitalsHumanHydrogen PeroxideHypochlorous AcidImmune responseIn VitroInfectionInflammationInflammation MediatorsInvestigationLeukocytesLigationLipidsLipopolysaccharidesMeasuresMediatingMediator of activation proteinMesenteryMicrobeMicrocirculationModelingMolecular BiologyMolecular TargetMorbidity - disease rateMultiple Organ FailureMyocardial InfarctionOrganOrgan failureOutcomeOxidantsOxygenPathologyPathway interactionsPatientsPeritonitisPeroxidasesPhagocytosisPhysiologicalPilot ProjectsPlasmaPlasmalogensPositioning AttributeProductionProteinsPuncture procedureRattusReceptor SignalingResearch DesignResearch PersonnelRobin birdRodentRodent ModelRoleSaintsSamplingSendai virusSepsisSeveritiesSeverity of illnessShockSplanchnic CirculationSurfaceSystemTestingTissuesUnited StatesUniversitiesUniversity HospitalsVascular PermeabilitiesVirusVirus DiseasesWashingtonantimicrobialcytokineendothelial dysfunctionfollow-uphuman dataimproved outcomein vivoinflammatory markerinhibitor/antagonistinnovationinsightinterdisciplinary approachintravital microscopykillingsleukocyte activationmast cellmicrobial hostmicrobicidemortalitymultidisciplinaryneutrophilnew therapeutic targetnovelnovel diagnosticsnovel therapeuticsresponseseptictherapeutic effectivenessvascular endothelial dysfunctionvinyl ether
项目摘要
DESCRIPTION (provided by applicant): Sepsis is a major cause of morbidity and mortality in both adults and children with an estimated 750,000 cases per year in the United States. To improve outcomes in these patients, it is vital to increase our understanding of the pathophysiology of the disease and identify new therapeutic targets. Sepsis occurs when the tightly controlled host response to infection extends beyond the local environment and into the systemic circulation. This results in complex interactions involving microbes, blood cells, and the
endothelial barrier in the microcirculation that can progress to vascular collapse and organ failure. Neutrophils are key early responders to infection. Neutrophils kill microbes by phagocytosis and by oxidant-mediated microbe killing in the surrounding environment. Myeloperoxidase (MPO) is a major mediator of oxygen-dependent microbicidal activity. MPO catalyzes the conversion of H2O2 to the potent oxidant, hypochlorous acid (HOCl), which reacts with both microbial and host molecular targets including proteins and lipids. The Ford group at Saint Louis University (SLU) has used physiological, biochemical and bio-organic approaches to demonstrate that the vinyl ether bond at the sn-1 position of plasmalogen lipids is targeted by HOCl, resulting in the production of 2-chlorofatty aldehyde, which is metabolized to 2-chlorofatty acid under physiological and pathophysiological conditions. These chlorinated lipids are elevated in activated neutrophils as well as in in vivo inflammation models including LPS treatment, Sindai virus exposure and peritonitis. Pilot studies show elevated levels of chlorinated lipids in a rat model of sepsis, and in human plasma of sepsis patients compared to controls. Additional preliminary data provide strong evidence that chlorinated lipids modulate leukocyte, platelet and endothelial cell function in the microcirculation and in isolated cell systems. Accordingly, we have assembled a multidisciplinary group with three PIs to test our hypothesis that chlorinated lipids produced by activated leukocytes during sepsis are mediators of severe endothelial dysfunction resulting in multiple organ failure. This hypothesis will be tested by three specific aims. Specific Aim 1 will test the hypothesis that chlorinated lipids produced by neutrophils are key mediators of endothelial dysfunction and organ damage during sepsis. Specific Aim 2 will test the hypothesis that chlorinated lipids mediate dysfunction in human endothelial cells. Specific Aim 3 will test the hypothesis that plasma 2-ClFA levels indicate both severity and therapeutic effectiveness in sepsis patients. Overall, a multi-disciplinary approach will examine the role of chlorinated lipids produced as a result of leukocyte
activation during sepsis as indicators of the severity of human sepsis, and mediators of vascular endothelial dysfunction examined both in vivo in the rat microcirculation and in vitro for mechanistic insights. The project is innovative and significant. These studies are designed to discover new paradigms for the role of neutrophils in eliciting endothelial dysfunction providing new targets for therapeutics to treat septic patients.
描述(申请人提供):败血症是成人和儿童发病和死亡的主要原因,据估计,美国每年有75万例败血症。为了改善这些患者的预后,增加我们对疾病病理生理学的理解并确定新的治疗靶点是至关重要的。当受到严格控制的宿主对感染的反应超出局部环境并进入体循环时,就会发生败血症。这导致了复杂的相互作用,涉及微生物、血细胞和
微循环中的内皮屏障,可进展为血管衰竭和器官衰竭。中性粒细胞是感染的关键早期反应者。中性粒细胞通过吞噬和氧化剂介导的微生物杀死周围环境中的微生物。髓过氧化物酶(MPO)是氧依赖性杀菌活性的主要介体。MPO催化过氧化氢转化为强氧化剂次氯酸(HOCl),次氯酸与微生物和宿主分子靶标包括蛋白质和脂质发生反应。圣路易斯大学(SLU)的Ford小组使用生理、生化和生物有机方法证明,血浆原脂质sn-1位的乙烯基醚键是HOCl的靶标,导致2-氯脂肪醛的产生,在生理和病理生理条件下,2-氯脂肪醛被代谢成2-氯脂肪酸。这些氯化脂质在激活的中性粒细胞以及体内炎症模型中都会升高,这些炎症模型包括内毒素治疗、信代病毒暴露和腹膜炎。初步研究表明,与对照组相比,脓毒症大鼠模型和脓毒症患者的人类血浆中氯化脂质水平升高。更多的初步数据提供了强有力的证据,表明氯化脂质在微循环和分离细胞系统中调节白细胞、血小板和内皮细胞的功能。因此,我们组建了一个由三个PI组成的多学科小组来验证我们的假设,即脓毒症期间激活的白细胞产生的氯化脂质是导致多器官衰竭的严重内皮功能障碍的介质。这一假设将通过三个具体目标进行检验。具体目标1将验证中性粒细胞产生的氯化脂质是脓毒症期间内皮功能障碍和器官损害的关键介质的假设。《特定目标2》将检验氯化脂质介导人类内皮细胞功能障碍的假设。具体目标3将检验这一假设,即血浆2-ClFA水平表明脓毒症患者的严重程度和治疗效果。总体而言,多学科方法将检查由于白细胞产生的氯化脂质的作用。
脓毒症期间的激活作为人类脓毒症严重程度的指示器,以及血管内皮功能障碍的介体,在体内和体外进行了大鼠微循环和体外机制的研究。该项目具有创新性和重大意义。这些研究旨在发现中性粒细胞在引发内皮功能障碍中的作用的新范例,为治疗败血症患者提供新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID A. FORD其他文献
DAVID A. FORD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID A. FORD', 18)}}的其他基金
Halolipid-Neutrophil Extracellular Trap Axis in Halogen Lung Injury
卤素肺损伤中的氟脂-中性粒细胞胞外俘获轴
- 批准号:
10685387 - 财政年份:2022
- 资助金额:
$ 45.99万 - 项目类别:
Halolipid-Neutrophil Extracellular Trap Axis in Halogen Lung Injury
卤素肺损伤中的氟脂-中性粒细胞胞外俘获轴
- 批准号:
10507044 - 财政年份:2022
- 资助金额:
$ 45.99万 - 项目类别:
Chlorinated lipid modification of proteins: Biomarkers of chlorine gas exposure
蛋白质的氯化脂质修饰:氯气暴露的生物标志物
- 批准号:
10160912 - 财政年份:2020
- 资助金额:
$ 45.99万 - 项目类别:
Chlorinated Lipids in Myocardial Ischemia/Reperfusion
氯化脂质在心肌缺血/再灌注中的作用
- 批准号:
8227162 - 财政年份:2012
- 资助金额:
$ 45.99万 - 项目类别:
Chlorinated Lipids in Myocardial Ischemia/Reperfusion
氯化脂质在心肌缺血/再灌注中的作用
- 批准号:
8403793 - 财政年份:2012
- 资助金额:
$ 45.99万 - 项目类别:
Serum chlorinated lipids as predictors of cardiovascular risk in lupus
血清氯化脂质作为狼疮心血管风险的预测因子
- 批准号:
7897511 - 财政年份:2010
- 资助金额:
$ 45.99万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 45.99万 - 项目类别:
Fellowship Programs














{{item.name}}会员




